Offering new hope
in the battle against antibiotic
resistant bacteria

Welcome to Auspherix

Auspherix is an anti-infectives company that is developing a novel class of organogold-based antibiotics that are designed to help address the worldwide healthcare crisis of rising antimicrobial resistance (AMR).

Research & Development

Our proprietary organogold chemistry platform is being used to build a pipeline of novel antibacterials with an initial therapeutic focus on complicated urinary tract (cUTI) infections.

read more »

Partnering

Whilst Auspherix is committed to progressing its pipeline of organogold compounds into clinical development, it welcomes strategic partnering opportunities with pharma and biotech companies in the anti-infectives space to expand its R&D capabilities and pipeline.

read more »

Investors

Auspherix is a private biotechnology company that is backed by leading sector investors namely Brandon Capital through the Australian Medical Research Commercialisation Fund (MRCF) and UK-based Touchstone Innovations.

read more »

Scientists Present Positive Progress in the Development of a New Class of Broad-Spectrum Organogold Antibiotics

Poster and Oral Presentation at the 19th RSC / SCI Medicinal Chemistry Symposium, 10th-13th September 2017, Churchill College, Cambridge, UK Cambridge, UK and Stevenage, UK – 12 September 2017 – Domainex and Auspherix have announced new data from their collaboration to develop novel candidate drugs to tackle the growing threat of resistance to antibiotics. The exciting data, disclosed […]

Auspherix to Present Organogold Pipeline at Superbugs & Superdrugs

Stevenage, UK – 20 March 2017 – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, is pleased to announce that it has been invited to present at this year’s Superbugs & Superdrugs conference in London, 20-21 March 2017. Chief Scientific Officer Richard Rutter will […]

December 2016 – PharmaVentures TV

Interview with CEO, Dr Neil Miller, discussing how Auspherix is meeting the urgent need for new antibiotics by developing a new class of organogold antibiotics.

View video on the PharmaVentures TV website

November – MedNous

Interview with CEO, Dr Neil Miller in an article about “The Stately Progress of Antibiotics”.

View PDF

November 2016 – Scrip TV

Interview with CEO, Dr Neil Miller.

Latest Tweets